PARP inhibitorPhase 3 trialInvestigational
Talazoparib
How it works
Blocks the enzyme that helps repair damaged DNA, making it harder for cancer cells to grow and divide.
Cancer types
Efficacy
Talazoparib has shown promise in improving progression-free survival in BRCA1/2-mutated ovarian cancer patients, with a median progression-free survival of approximately 8 months.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Talazoparib with or without Enzalutamide in Men with Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Understanding Cancer Cells' Resistance to Treatment | Breast Cancer | lab-study | — | Source → |
| Understanding Resistance to Cancer Treatment in Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Testing Talazoparib and Radiation Therapy for Locally Recurrent Gynecologic Cancers | Ovarian Cancer | phase-1 | — | Source → |
| Study of Talazoparib and Enzalutamide in Men with Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Talazoparib Trial for Advanced Cancer | Breast Cancer | phase-2 | — | Source → |
| PARP Inhibitor Talazoparib Shows Promise in Treating Breast and Ovarian Cancers | Breast Cancer | review | Talazoparib has the highest potency (IC = 0.57 nM), which is 4-10 times lower than that of other PARP inhibitors. | Source → |
| New Formulation of Cancer Drug Talazoparib Gets Approval | Prostate Cancer | phase-3 | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| New Combination Therapy May Improve Prostate Cancer Outcomes | Prostate Cancer | phase-3 | Talazoparib plus enzalutamide was statistically superior to olaparib plus abiraterone acetate for radiographic progression-free survival (HR: 0.727; 95% confidence interval [CI]: 0.565, 0.935) | Source → |
| New Study Compares Treatments for Advanced Prostate Cancer | Prostate Cancer | meta-analysis | Talazoparib in combination with enzalutamide achieved a hazard ratio of 0.20 for radiographic progression-free survival. | Source → |
| Talazoparib Resistance Linked to Cancer Cell Transporters | Ovarian Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.